AstraZeneca’s (AZN) Hold Rating Reiterated at Liberum Capital

Liberum Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Monday.

AZN has been the topic of several other reports. UBS Group reaffirmed a neutral rating and issued a GBX 5,600 ($72.95) price objective on shares of AstraZeneca in a research report on Monday, July 2nd. Deutsche Bank cut their price objective on shares of AstraZeneca from GBX 6,000 ($78.16) to GBX 5,700 ($74.25) and set a buy rating on the stock in a research report on Friday, July 20th. BNP Paribas set a GBX 6,500 ($84.67) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Tuesday, September 11th. Barclays set a GBX 6,500 ($84.67) price objective on shares of AstraZeneca and gave the company a buy rating in a research report on Friday, July 27th. Finally, JPMorgan Chase & Co. set a GBX 5,800 ($75.55) price target on shares of AstraZeneca and gave the company a buy rating in a research note on Monday, July 9th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of GBX 5,689.45 ($74.11).

AZN opened at GBX 5,870 ($76.46) on Monday. AstraZeneca has a 12 month low of GBX 4,260 ($55.49) and a 12 month high of GBX 5,520 ($71.90).

The firm also recently declared a dividend, which was paid on Monday, September 10th. Shareholders of record on Thursday, August 9th were paid a GBX 68.40 ($0.89) dividend. The ex-dividend date of this dividend was Thursday, August 9th. This represents a yield of 1.19%.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: How Short Selling Works

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply